Clinical Trials Logo

DLBCL, Nos Genetic Subtypes clinical trials

View clinical trials related to DLBCL, Nos Genetic Subtypes.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05757700 Recruiting - B-Cell Lymphoma Clinical Trials

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Start date: February 23, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma. Researchers will also evaluate if this study therapy is safe, and to look for the highest dose that causes few or mild side effects in participants.

NCT ID: NCT05583149 Recruiting - Clinical trials for Refractory B-Cell Non-Hodgkin Lymphoma

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce

NCT ID: NCT04512716 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Start date: February 2, 2021
Phase: Early Phase 1
Study type: Interventional

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.